(1) Consists of 8,913,331 shares of common stock held by FMR LLC, or FMR, of which it has sole voting power and sole dispositive power as to 8,913,331 shares of common stock. The principal address of FMR is 245 Summer Street, Boston, Massachusetts 02210. The foregoing information is based solely upon a Schedule 13G/A filed with the SEC on February 9, 2023.
(2) Consists of 8,278,876 shares of common stock held by Atlas Venture Life Science Advisors, LLC, or Atlas, of which it has sole voting power and sole dispositive power as to 8,278,876 shares. Jason Rhodes is an affiliate of Atlas. The principal address for Atlas is 300 Technology Square, 8th Floor, Cambridge, MA 02139. The foregoing information is based solely on a Form 13F filed by Atlas with the SEC on February 14, 2023.
(3) Consists of (i) 7,261,046 shares of common stock held by T. Rowe Price Associates, Inc., or T. Rowe Price Associates, of which it has sole voting power as to 1,360,888 shares of common stock and sole dispositive power as to 7,261,046 shares of common stock, and (ii) 3,471,528 shares of common stock held by T. Rowe Price New Horizons Fund, Inc., or New Horizons Fund, of which it has sole voting power as to 3,471,528 shares of common stock and sole dispositive power as to none. The principal address of T. Rowe Price Associates and New Horizons Fund is 101 E. Pratt Street, Baltimore, MD 21201. The foregoing information is based solely upon a Schedule 13G/A filed by T. Rowe Price Associates, Inc. with the SEC on February 14, 2023.
(4) Consists of 5,859,375 shares of common stock held by ModernaTx, Inc., or Moderna, of which it has sole voting power and sole dispositive power as to 5,859,375 shares of common stock. The principal address for Moderna is 200 Technology Square Cambridge, MA 02139. The foregoing information is based solely upon a Schedule 13G filed by Moderna with the SEC on March 24, 2023.
(5) Consists of 3,708,067 shares of common stock held by BlackRock, Inc., or BlackRock, of which it has sole voting power as to 3,610,260 shares of common stock and sole dispositive power as to 3,708,067 shares of common stock. The principal address for BlackRock is 55 East 52nd Street, New York, NY 10055. The foregoing information is based solely on a Schedule 13G/A filed by BlackRock with the SEC on February 1, 2023.
(6) Consists of (i) 3,608,280 shares of common stock held by BB Biotech AG, or BB Biotech, of which it has shared voting power and shared dispositive power as to 3,608,280 shares of common stock and (ii) 3,608,280 shares of common stock held by Biotech Growth N.V., or Biotech Growth, of which they have shared voting power and shared dispositive power as to 3,608,280 shares of common stock. The principal address for BB Biotech is Schwertstrasse 6, CH-8200 Schaffhausen, Switzerland and the principal address for Biotech Growth is Ara Hill Top Building, Unit A-5, Pletterijweg Oost 1, Curaçao. Biotech Growth is a wholly-owned subsidiary of BB Biotech. The foregoing information is based solely on a Schedule 13G/A filed by BB Biotech with the SEC on February 14, 2023.
(7) Consists of 3,577,755 shares of common stock held by T. Rowe Price Investment Management, Inc., of which it has sole voting power as to 1,092,446 shares of common stock and sole dispositive power as to 3,577,755 shares of common stock. The principal address of T. Rowe Price Investment Management, Inc. is 101 E. Pratt Street, Baltimore, MD 21201. The foregoing information is based solely upon a Schedule 13G filed by T. Rowe Price Investment Management, Inc. with the SEC on February 14, 2023.
(8) Includes 73,200 shares of common stock issuable upon the exercise of options that are exercisable as of the Record Date or will become exercisable within 60 days of such date.
(9) Consists of (i) 1,239,510 shares of common stock held directly, (ii) 420,098 shares of common stock issuable upon the exercise of options that are exercisable as of the Record Date or will become exercisable within 60 days of such date, (iii) 23,437 shares of common stock issuable upon the vesting of restricted stock units within 60 days of the Record Date, (iv) 226,462 shares of common stock held by the McDonough Family 2018 Irrevocable Trust, or the 2018 Trust, and (v) 275,000 shares of common stock held by the McDonough Family 2020 Irrevocable Trust, or the 2020 Trust. Dr. McDonough is the settlor of the 2018 Trust, Allison L. McDonough and David S. Grayzel are trustees for the 2018 Trust and the 2018 Trust is for the benefit of Graeme and Owen McDonough. Dr. McDonough is the settlor of the 2020 Trust, Allison L. McDonough and David S. Grayzel are trustees for the 2020 Trust and the 2020 Trust is for the benefit of Allison, Graeme and Owen McDonough. Dr. McDonough may be deemed to beneficially own the shares of common stock owned by the 2018 and 2020 Trusts.
(10) Consists of (i) 20,623 shares of common stock held directly, (ii) 285,963 shares of common stock issuable upon the exercise of options that are exercisable as of the Record Date or will become exercisable within 60 days of such date, and (iii) 7,437 shares of common stock issuable upon the vesting of restricted stock units within 60 days of the Record Date.
(11) Consists of (i) 351,526 shares of common stock held directly, (ii) 196,638 shares of common stock issuable upon the exercise of options that are exercisable as of the Record Date or will become exercisable within 60 days of such date, and (iii) 7,437 shares of common stock issuable upon the vesting of restricted stock units within 60 days of the Record Date.
(12) Consists of (i) 218,777 shares of common stock held directly, (ii) 237,429 shares of common stock issuable upon the exercise of options that are exercisable as of the Record Date or will become exercisable within 60 days of such date, and (iii) 7,437 shares of common stock issuable upon the vesting of restricted stock units within 60 days of the Record Date.